BBNX — Beta Bionics Cashflow Statement
0.000.00%
Last trade - 00:00- $474.89m
- $255.76m
- $100.25m
Annual cashflow statement for Beta Bionics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -64.8 | -44.1 | -54.8 | -73.2 |
| Depreciation | ||||
| Non-Cash Items | 5.99 | 15.7 | 17.5 | 29.7 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -2.79 | -5.3 | -12.1 | -8.99 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -60.2 | -32.4 | -48.3 | -50.9 |
| Capital Expenditures | -0.772 | -0.402 | -3.4 | -5.3 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | 0.003 | -69.3 | -0.081 | -158 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -0.769 | -69.7 | -3.48 | -163 |
| Financing Cash Flow Items | — | — | -4.15 | 0 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 56.8 | 101 | 55.6 | 215 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -4.2 | -1.11 | 3.87 | 1.14 |